Clinical trials: Stereotactic Radiotherapy
Unresectable Locally Recurrent Rectal Cancer
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
This is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer…
- Trial name
- NCT06767007
- Testing
- Stereotactic Body Radiation Therapy (SBRT), PD1, Chemotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cardiotoxicity
Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be included. Participants will be randomly divided into experimental group or control group.
- Trial name
- NCT04939857
- Testing
- Trimetazidine
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Prostate Cancer
ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Trial name
- ABRUPT (NCT04831983)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Pancreatic Carcinoma Non-resectable
Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer
Currently the standard treatment for locally advanced, unresectable pancreatic cancer consists either of chemotherapy by itself or a combination of chemotherapy plus radiation therapy or no treatment at all.
- Trial name
- NCT01872377
- Testing
- CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Ottawa Hospital Research Institute
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Pancreatic Cancer, Retroperitoneal Pain Syndrome
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Participants who are experiencing abdominal pain due to having cancer in their pancreas may be eligible for this research study. For this type of pain, doctors often recommend radiation therapy to help with the pain.
- Trial name
- NCT07117032
- Testing
- Simulation-free workflow, Celiac plexus SBRT
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Tumors
Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
- Trial name
- NCT02933242
- Testing
- Stereotactic Ablative Body Radiotherapy
- Where
- Canada
- Volunteers
- 399 people
- Sponsor
- British Columbia Cancer Agency
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack…
- Trial name
- EMPIRE (NCT06843551)
- Testing
- Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Benjamin Spieler
Prostate Cancer (Adenocarcinoma)
Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer.
- Trial name
- SPAR (NCT07344844)
- Testing
- Low-dose CT imaging before each SBRT session
- Where
- Reunion
- Volunteers
- 100 people
- Sponsor
- Clinique Sainte Clotilde
Brain Metastases
Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis
This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the…
- Trial name
- NeoSTROBE (NCT06933199)
- Testing
- Neoadjuvant Stereotactic Radiotherapy (NaSRT), Postoperative Stereotactic Radiotherapy (SRT)
- Where
- 4 sites in Czechia
- Volunteers
- 260 people
- Sponsor
- University Hospital Ostrava
Lung Cancer, Oligometastatic Lung Tumor
One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors
Stereotactic body radiotherapy (SBRT) has become a standard of care for medically inoperable or high-risk operable early-stage non-small cell lung cancer (NSCLC) patients.
- Trial name
- ONE STOP (NCT06236516)
- Testing
- One fraction stereotactic body radiotherapy, HyperSight, Ethos
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer, Cervical Cancer Recurrent
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent…
- Conditions
- Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
- Trial name
- NCT03614949
- Testing
- Stereotactic body radiation therapy (SBRT), Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastases
A Proof-of-principle Study of HBO-SRS for Brain Metastases
Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants.
- Trial name
- NCT01850563
- Testing
- Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Recurrent Pancreatic Ductal Adenocarcinoma
Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy…
- Trial name
- ARCADE (NCT04881487)
- Testing
- Additional stereotactic body radiation therapy
- Where
- 3 sites in Netherlands
- Volunteers
- 174 people
- Sponsor
- UMC Utrecht
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Prostate Cancer, Prostate Adenocarcinoma
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01856855
- Testing
- Stereotactic Body Radiation Therapy with Integrated Boost
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Fiveash, MD
Lung Cancer
Design and Evaluation of a Novel Methodology for SABR for Lung Cancer
Aims: To increase the number of patients that benefit from Stereotactic Ablative Radiotherapy (SABR) for lung cancer using new treatment methods that reduce the amount of non-cancer tissue receiving a high radiation dose without…
- Trial name
- NCT04928755
- Volunteers
- 30 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.